Huntington’s Disease Clinical Trials Corner: August 2023

In this edition of the Huntington’s Disease Clinical Trials Corner, we expand on the GENERATION HD2 (tominersen) and on the Asklepios Biopharmaceutical/BrainVectis trial with AB-1001. We also comment on the recent findings from the PROOF-HD trial, and list all currently registered and ongoing clinic...

Full description

Saved in:
Bibliographic Details
Published inJournal of Huntington's disease Vol. 12; no. 2; pp. 169 - 185
Main Authors Estevez-Fraga, Carlos, Tabrizi, Sarah J., Wild, Edward J.
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.01.2023
Sage Publications Ltd
IOS Press
Subjects
Biopharmaceuticals
Clinical trials
Clinical Trials Corner
Huntington's disease
Huntingtons disease
clinical trials
Huntington disease
Online AccessGet full text

Cover

More Information
Summary:In this edition of the Huntington’s Disease Clinical Trials Corner, we expand on the GENERATION HD2 (tominersen) and on the Asklepios Biopharmaceutical/BrainVectis trial with AB-1001. We also comment on the recent findings from the PROOF-HD trial, and list all currently registered and ongoing clinical trials in Huntington’s disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
Postal Address: UCL Huntington’s Disease Centre. 2nd Floor Russell Square House. 10-12 Russell Square. London, UK.
ISSN:1879-6397
1879-6397
DOI:10.3233/JHD-239001